

# CUMULATIVE YEAR-END INDEX—2002

## SMALL ANIMAL/EXOTICS AUTHOR INDEX

**A**

- Alleman, A. R., 798
- Anderson, M. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Anderson, W., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Appel, M. J. G., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Applewhite, A. A., 110
- Arther, R.G., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

**B**

- Ballam, J., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Barr, S. C., 304, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Barrs, V. R., 184
- Barten, S. L., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
- Beckman, B., 439
- Biery, D. N., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Binnington, A. G., 41, 53
- Blagburn, B. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Bledsoe, D. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Boswood, A., 316
- Bowers, L. C., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Breitschwerdt, E. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Broce, A. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Buonomo, F. C., *Veterinary Therapeutics Highlights*, December supplement (12A)

**C**

- Cahill-Morasco, R., 712
- Calvert, C. A., 614
- Campbell, K. L., 224
- Carithers, D., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Ciszewski, D., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Cohn, L. A., 277
- Cooper, C., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Cornell, K. K., 110
- Corrada, Y., 99, 778
- Côté, E., 701

**D**

- Daniel, G. B., 626
- Davidson, G., 600
- Denholm, I., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- DePasquale, M. A., 712
- Dryden, M. W., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Dykes, N. L., 25

**E**

- Eddlestone, S. M., 452
- El Bahri, L., 884
- Endepols, S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Evermann, J. E., 390

**F**

- Flatland, B., 688
- Frank, G., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Fontenot, D. K., 550
- Ford, R. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Fordyce, H. H., 526
- Foster, S. E., 184
- Freeman, L. M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

**G**

- Gannon, K. M., 604
- Garcia-Lacaze, M., 758
- Garner, M. M., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
- Gauthier, J. L., *Bayer Zoonosis Symposium*, May supplement (5A)
- Gil, M. C., 400, 556
- Gobello, C., 99, 778
- Gorham, J. R., 390
- Greenacre, C. B., 550
- Greene, C. E., 614
- Gulikers, K. P., 511
- Guptill, L., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

**H**

- Hanscom, J. L., *Veterinary Therapeutics Highlights*, December supplement (12A)
- Hansen, O., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

- Harari, J., 908, 918
- Harpster, N., 364, 470, 478
- Head, E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Head, L. L., 858
- Hess, R. S., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Hodgkins, E., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Hoenig, M., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Hopkins, T., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Hunt, G. B., 184

**J**

- Jacobs, D. E., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Jacobs, M. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Jones, P. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

**K**

- Kapatkin, A. S., 526, 590, 681
- Katayama, M., 868, 874
- Kazakos, G. M., 204
- Kazakos, K. R., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Kealy, R. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Keil, K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Kelly, M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Kirby, R., 758, 922
- Kitchell, B. E., 220
- Kocan, A. A., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

**L**

- Laflamme, D. P., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A), *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Lamb, C. R., 316, 626
- Langer, N., 446
- Langston, C., 540
- Lappin, M. R., *Bayer Zoonosis Symposium*, May supplement (5A)
- Larsen, K. S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Lawler, D. E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

# CUMULATIVE YEAR-END INDEX—2002

## SMALL ANIMAL/EXOTICS AUTHOR INDEX

**A**

- Alleman, A. R., 798
- Anderson, M. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Anderson, W., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Appel, M. J. G., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Applewhite, A. A., 110
- Arther, R.G., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

**B**

- Ballam, J., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Barr, S. C., 304, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Barrs, V. R., 184
- Barten, S. L., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
- Beckman, B., 439
- Biery, D. N., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Binnington, A. G., 41, 53
- Blagburn, B. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Bledsoe, D. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Boswood, A., 316
- Bowers, L. C., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Breitschwerdt, E. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Broce, A. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Buonomo, F. C., *Veterinary Therapeutics Highlights*, December supplement (12A)

**C**

- Cahill-Morasco, R., 712
- Calvert, C. A., 614
- Campbell, K. L., 224
- Carithers, D., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Ciszewski, D., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Cohn, L. A., 277
- Cooper, C., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Cornell, K. K., 110
- Corrada, Y., 99, 778
- Côté, E., 701

**D**

- Daniel, G. B., 626
- Davidson, G., 600
- Denholm, I., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- DePasquale, M. A., 712
- Dryden, M. W., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Dykes, N. L., 25

**E**

- Eddlestone, S. M., 452
- El Bahri, L., 884
- Endepols, S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Evermann, J. E., 390

**F**

- Flatland, B., 688
- Frank, G., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Fontenot, D. K., 550
- Ford, R. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Fordyce, H. H., 526
- Foster, S. E., 184
- Freeman, L. M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

**G**

- Gannon, K. M., 604
- Garcia-Lacaze, M., 758
- Garner, M. M., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
- Gauthier, J. L., *Bayer Zoonosis Symposium*, May supplement (5A)
- Gil, M. C., 400, 556
- Gobello, C., 99, 778
- Gorham, J. R., 390
- Greenacre, C. B., 550
- Greene, C. E., 614
- Gulikers, K. P., 511
- Guptill, L., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

**H**

- Hanscom, J. L., *Veterinary Therapeutics Highlights*, December supplement (12A)
- Hansen, O., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

- Harari, J., 908, 918
- Harpster, N., 364, 470, 478
- Head, E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Head, L. L., 858
- Hess, R. S., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Hodgkins, E., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Hoenig, M., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Hopkins, T., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Hunt, G. B., 184

**J**

- Jacobs, D. E., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Jacobs, M. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Jones, P. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

**K**

- Kapatkin, A. S., 526, 590, 681
- Katayama, M., 868, 874
- Kazakos, G. M., 204
- Kazakos, K. R., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
- Kealy, R. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Keil, K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Kelly, M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
- Kirby, R., 758, 922
- Kitchell, B. E., 220
- Kocan, A. A., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

**L**

- Laflamme, D. P., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A), *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
- Lamb, C. R., 316, 626
- Langer, N., 446
- Langston, C., 540
- Lappin, M. R., *Bayer Zoonosis Symposium*, May supplement (5A)
- Larsen, K. S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
- Lawler, D. E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Legendre, L., 439

L'Epattienier, H., 234, 292

*Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Levy, S. A., *Veterinary Therapeutics Highlights*, December supplement (12A)

Li, Y., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Liang, F. T., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Lindsay, D. S., 304

Linnell, M., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Lucroy, M. D., 128, 140

## M

Mader, D. R., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)

Malik, R., 184

Mathews, K. A., 41, 53

Matousek, J. L., 224

Mayhew, P. D., 526, 590, 681

McAnulty, J. E., 868, 874

McCracken, B., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

McDonough, S., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

McKiernan, A. J., 390

McKiernan, B. C., 934, 944

McLaughlin, R. M., 836

Mealey, K. L., 10

Mehlhorn, H., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Meinkoth, J., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Melzer, K. J., 953

Mencke, N., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Michel, K. E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Millis, D. L., *Veterinary Therapeutics Highlights*, December supplement (12A)

Montavon, P., 234, 292

Morrow, C. K., 380

Moses, L., 604

Moyers, T., *Veterinary Therapeutics Highlights*, December supplement (12A)

## N

National Association of State Public Health Veterinarians, 328, 374

Neer, T. M., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Nicastro, A., 701

Nykamp, S. G., 25

## O

O'Connor, T. P., *Veterinary Therapeutics Highlights*, December supplement (12A)

Olson, M. E., *Bayer Zoonosis Symposium*, May supplement (5A)

## P

Panciera, D. L., 511

Papazoglou, L. G., 204

Payne, P. A., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Pazak, H., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Peña, E. J., 400, 556

Perkins, M. C., 184

Philipp, M. T., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Pool, R. R., 836

Pospischil, R., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Preziosi, D. E., 277

Prosek, R., 220

Purcell, J. E., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

## R

Ramiah, S. K., 798

Rand, J. S., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Read, M. R., 774

Reiss, A. J., 934, 944

Reuter, K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Richardson, D. J., *Bayer Zoonosis Symposium*, May supplement (5A)

Ritchie, B. W., 550

Rodriguez, D. B., 364, 470, 473

Rosenthal, K. L., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)

Rudloff, E., 758, 922

Rupprecht, C. E., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Rust, M. K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

## S

Sayer, A. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Schantz, P. M., *Emerging Vector-Borne and*

*Zoonotic Diseases*, January supplement (1A)

Schroeder, L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Scrivani, P. V., 25

Selzer, B. A., 110

Sellon, R. K., 953

Settje, T., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Shields, P., *Veterinary Therapeutics Highlights*, December supplement (12A)

Smith, G. K., 526, 590, 681, *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Smith, S. A., 670, 784

St. John, L. M., 92

Suber, T. W., 962

Swinney, G. R., 184

## T

Trostel, C. T., 836

## V

Vaughn, M. B., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Volmer, P. A., 380

## W

Wagoner, M., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Wall, M., 614

Watkins, B. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Watson, C. L., 128

Weigel, D. L., *Veterinary Therapeutics Highlights*, December supplement (12A)

Weiss, D. J., 670, 784

Wellington, J., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Willms, C., 922

Wilson, G. H., 550

Wingfield, W. E., 934, 944

## Y

Young, D. R., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

## Z

Zajac, A. M., 304

## VOLUME 24 PAGINATION: Small Animal/Exotics

Issue	Pages	Issue	Pages
January	1-60	July	501-561, 580
February	81-148	August	581-637
March	177-241	September	661-722, 747
April	265-335	October	749-811, 822
May	353-408, 428	November	829-887
June	429-482	December	909-963

# SMALL ANIMAL/EXOTICS SUBJECT INDEX<sup>a</sup>

## A

Abortion (see Mismatching and abortion, in bitches)

Antibiotic therapy, in exotic pets, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 5S-12S

## B

*Bartonella*, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 32S-35S

Bone marrow

collection and assessment of, canine, 670-679

aspiration biopsy technique, 671-672

aspiration smears, evaluation of, 674-677

core biopsy technique, 674

disorders, classification of, 677

indications, for bone marrow evaluation, 670-671

specimens, preparation of, 672-674

techniques, special, 677

interpretation of, canine, 784-797

hematologic disorders, associated with multiple cytopenias, 790-793

hematologic disorders, associated with neoplastic disorders, 793

hematologic disorders, associated with neutropenias, 789-790

hematopoietic disorders, associated with poorly regenerative anemias, 784-789

primary myelofibrosis, 793

Bone tumors, primary appendicular, in dogs, 128-138, 147

biopsy, 130

diagnostic differentials, 129-130

history and clinical signs, 129

metastasis, 133-134

prognostic factors, 134

radiography, 129

signalment, 128-129

staging, 130-131

treatment, 131-133

*Borrelia burgdorferi* infection, *Veterinary Therapeutics Highlights*, December supplement (12A), 18S-25S, 27S-31S

## C

Canine lameness (see Osteochondrosis)

Cardiac disease, canine, role of survey radiography in diagnosing, 316-326, 352

assessment, of cardiac shape, 320-321

assessment, of cardiac size, 317-320

radiographic signs, of cardiac failure, 321-325

<sup>a</sup>Page numbers ending in "S" indicate subjects that appeared in a supplement to *Compendium*.

Cardiopulmonary resuscitation, 922

advanced cardiac life support update, 924-929

basic cardiac life support update, 923-924

guidelines, standard, human, 923

Cefixime, 446-450

Chemotherapy safety, 140-147

animal wastes, 144

chemotherapy administration, 141-142

considerations, general, 140-141

drug extravasation, 142-143

fatal reactions, 144

hypersensitivity reactions, 143-144

personal protection equipment, 141

records, 142

work area, 141

*Chlamydia pneumoniae*, 328-335, 374-378

COX-2 inhibitor (see Deracoxib, effect of)

Cranial vena cava syndrome, 701-710, 741

clinical presentation, 702-705

diagnosis, 705-707

pathogenesis, 701-702

prognosis, 709

treatment, 707-709

Cytosine deaminase, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 7S-9S

## D

Deracoxib, effect of, *Veterinary Therapeutics Highlights*, December supplement (12A), 6S-17S

Desmopressin acetate, 962-963, 988

Dextroamphetamine, 220-222

Diabetes, feline, *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

diet aids, in treatment of, 20S

drug options, for managing, 7S-9S

protein diet, use of, in management of, 10S-16S

understanding, 2S-6S

urine glucose, monitoring of, S17-S19

Drug interactions, clinically significant, 10-22

drug class, specific drug interactions by, 12-19

incidence, 10-11

mechanisms, 11-12

## E

Ehrlichia, 277-289, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 15S-18S

classification, 277-278

clinical findings, 279-282

diagnosis, 282-283

epidemiology, 278

prevention and control, 284

transmission and pathogenesis, 279

treatment, 283-284

zoonotic potential, 284-285

Ehrlichiosis, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 10S-14S

Enteric Clostridial Colonization, in psittacine birds, 550-554

## F

Fleas

allergy dermatitis, efficacy in controlling, by Advantage<sup>®</sup>, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 6S-9S

control, integrated, for the 21<sup>st</sup> century, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 36S-40S

feeding, disruption of, by imidacloprid, Third International Flea & Tick Control Symposium, (4B), 4S-5S

imidacloprid plus permethrin vs. fipronil, evaluation of, 17S-20S

infestation, in exotic pet animals, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 10S-13S

susceptibility, of cat fleas, to imidacloprid, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 14S-16S

## G

Gastrointestinal disease, drug therapies used in, 452-469

antiemetics, 453-456

antimicrobials, 463-464

cytoprotective drugs and antacids, 458-459

emetics, 453

gastric antisecretory drugs, 456-458

immune-modulating drugs, 464-467

motility modifiers, 461-463

protectants, and adsorbents, 459-461

vomiting reflex, 452

Gerontology and longevity, 2001 *Purina Nutrition Forum Proceedings*, September supplement (9A)

body condition, influence of, on canine osteoarthritis, 8S-12S

cancer prevention, through nutrition, 28S-34S

cardiac disease, nutritional modulation of, 46S-49S

chondroitin sulfate, in prevention and management of osteoarthritis, 24S-27S

cognitive dysfunction, neurological basis for, in aging dogs, 35S-39S

diabetics, feline, nutritional management of, 550-555

early growth and nutrition, influence of, on aging, 45-75

glucosamine, in prevention and management of osteoarthritis, 245-275

immune function, changes in, with advancing age, 405-455

introduction, 15-35

osteoarthritis, management of, with nutraceuticals, 556-561

phytochemicals, in bone and joint metabolism, 135-235

Green iguana, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)

clinical pathology of, 235-265

management, and husbandry, 135-225

metabolic bone diseases in, 275-295

phosphorous levels in, 435-445

reproductive surgery in, 305-345

tail problems in, 355-375

## H

Hazardous drug administration (*see* Chemotherapy safety)

*Helicobacter* infection, in humans and animals, 688-698

diagnosis, 689-691

future, 695

pathogenesis, 689

treatment, 691-694

Hemodialysis, in dogs and cats, 540-549

complications, 546-548

indications for, 540-543

intradialytic management, 546

outcome, 548

prescription, 545-546

principles of, 544-545

procedures, 543-544

Hip dysplasia, canine

disease and diagnosis, 526-538

CHD diagnosis, 527-530

diagnosis and scoring, methods of, 530-535

genetic control of, 681-687

heritability, 682-685

relationship, between phenotype and genotype, 681

selection pressure, and strategy, for rapid genetic change, 685-686

treatment, evidence-based, 590-599

clients, informing about hip surgery, 593-594

efficacy, determining, 592-593

indications, for medical (nonsurgical) treatment, 594-596

orthopedic examination, and differential diagnosis, 594

prevention, possible treatments, 591

treatment outcome, 596-597

Hookworms (*see* Zoonotic ascarids)

Hypercalcemia, 380-388

metabolism, normal, 380-381

mineral imbalances, diagnostic differentials for, 382-386

parathyroid hormone interactions, 381

soft-tissue mineralization, lesions and prevention of, 386-387

vitamin D interactions, 381-382

Hyperphosphatemia (*see* Hypercalcemia)

Hypertrophic cardiomyopathy, feline, (*see also* Thromboembolism, aortic, associated with feline hypertrophic cardiomyopathy)

etiology, pathophysiology, and clinical features, 364-373

clinical features, 366-371

etiology, 364-365

pathophysiology, 365-366

treatment of, 470-476

angiotensin-converting enzyme inhibitors, 474

$\beta$ -blockers, 472

calcium-channel blockers, 472-474

diuretic therapy, 470-472

nitroglycerin, 472

prognosis, 474-475

## I

Iguana (*see also* Green iguana), oral cavity, disease of, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 385-425

Infective endocarditis, in dogs, 614-625

bacteremia and adherence, 614-616

clinical findings, 617-618

clinical pathology, 618

diagnosis, 619-621

diagnostics, special, 618-619

epizootiology, 616

pathophysiology, 617

predisposing factors, 616-617

prevention, 623

prognosis, 623

treatment, 621-623

valve involvement, 616

Intestinal lymphangiectasia, canine, 953-961

clinical findings, 954-955

diagnosis, 955-958

diagnostic testing, 955

pathogenesis and etiology, 953-954

prognosis, 959

treatment, 958-959

Intussusceptions, diagnosis and treatment of, in dogs, 110-127

future prospects, 125

gastroesophageal intussusceptions, 111-116

intestinal intussusceptions formation, mechanisms of, 111

intestinal intussusceptions, 118-125

pyloric intussusceptions, 116-118

## L

Lameness, canine (*see* Deracoxib, effect of)

Larva migrans, from pets and wildlife, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 415-465

Leishmaniasis

in American foxhounds, 304-313

clinical signs, in dogs, 305-306

diagnosis and antibody responses, 306

endemic infections, in the United States, 309-310

future considerations, 310

life cycle, 304-305

treatment, 306-309

in North America, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 35-65

Leptospirosis, new issues and considerations, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 535-565

Longevity (*see* Gerontology and longevity)

Liver, cytologic evaluation of, 798-810

Indications for, 799

sampling techniques, 799-809

Lyme disease

in dogs, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 195-235

new standards, for diagnosis of, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 245-275

## M

Malassezia dermatitis, 224-232

associated diseases, 227

classification, 224-225

cutaneous and mucosal colonization, 225

diagnosis, 227-228

predisposing factors, 226-227

treatment, 228-229

virulence factors, 225-226

Midazolam, 774-777

Mismating and abortion, in bitches

preattachment period, 400-408

antiprogesterins, 406-407

biology, and endocrinology, of pregnancy, 401

early pregnancy detection, 401-402

estrogens, 404-406

prostaglandins, 406

stepwise approach, 400-401

timing, 402-404

proliferation period, 556-561

abortion induction, monitoring of, 559

abortion induction protocols, 557-559

postovulation period, 559

Myocardial injury

diagnosis and treatment, 944-952

incidence and pathophysiology, 934-941

## N

Nasopharyngeal disorders, of dogs and cats, 184-200



clinical signs of disease, 185  
 clinical retrospective study, 190-197  
 diagnosis, 185-187  
 discussion, 197-198  
 nasopharynx, access to, 187-190

Nerve blocks (see Oral surgery, regional nerve blocks for, in companion animals)

Nutrition (see Gerontology and longevity)

## O

Oral surgery, regional nerve blocks for, in companion animals, 439-444

agent and dose, 440  
 benefits, 439  
 complications, 442  
 materials, 440  
 oral cavity, regional nerve blocks of the, 440-442

Osteochondrosis, 836-854

of the elbow, 845-846  
 of the hock, 848-850  
 of the shoulder, 840-845  
 of the stifle, 846  
 overview, 837-840

Otitis, canine, *Veterinary Exchange*, March supplement (3A)

otitis media, diagnosis, treatment, and management of, 45-95  
 otitis media, potential causes of, 105-205

## P

Patellar luxation, in dogs and cats

pathogenesis and diagnosis, 234-240  
 anatomy and biomechanics, 234-235  
 clinical signs and diagnosis, 237-238  
 pathogenesis, 235-237  
 management and prevention, 292-300  
 prevention, 296-297  
 prognosis, 296  
 treatment, 293-296

Penis and prepuce, surgical conditions of the canine, 204-218

Peritoneal dialysis, 758-772

case study, 766  
 catheter placement, 761-762  
 catheter selection, 761  
 clinical use, 768-770  
 complications, 767-768  
 dialysate, and additives, 760-761  
 exchange procedure, 762-763  
 mechanism of, 758-760  
 nursing instructions, 763-765  
 patient factors, 760  
 stopping, 768

Portosystemic shunting, diagnostic imaging of dogs with suspected, 626-635

diagnostic imaging, role of, 627-633  
 prognosis, assessment of, 633-634

Pralidoxime, 884-886

Pregnancy loss, noninfectious spontaneous, in bitches, 778-783

bilateral occlusions, of the uterus, 780  
 clinical approach, 778-779  
 cystic endometrial hyperplasia, 780  
 drugs, 780-781  
 endocrine disorders, nonsexual, 779  
 genetics, 781  
 miscellaneous causes, 781-782  
 nutrition, 781  
 progesterone deficiency, 779-780

Prostatic diseases, noninfectious, in dogs, 99-108

benign prostatic hyperplasia, 99-102  
 discussion, 104-105  
 prostatic cysts, 102  
 prostatic markers, 104  
 prostatic neoplasia, 102-104  
 squamous metaplasia, 102

Pulmonary disease, radiographic signs of, 25-36  
 clinical applications, 33-34  
 radiographic signs, using, instead of patterns, 26-32

Pyridostigmine, 92-94

## R

Rabies, reemergence, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 57S-60S

Radiation safety, improving, in the veterinary hospital, 858-867

barrier design, 865-866  
 equipment maintenance, 866  
 exposure levels, personal, 859-862  
 exposure, radiation, factors affecting, 862-864  
 ionizing radiation, effects of, 858-859  
 monitoring devices, 864  
 units, of exposure, 864-865

Radiography (see Cardiac disease, canine, role of survey radiography in diagnosing; Pulmonary disease, radiographic signs of)

Recombinant vaccine technology, *Recombinant Vaccine Technology*, April supplement (4A), 15-16S

Renal disease, progressive, in dogs, *Current Understanding of Progressive Renal Disease in Dogs*, March supplement (3B), 15-12S

Renal transplantation, in cats

patient selection, and preoperative management, 868-873  
 preoperative management, of recipient, 872  
 risk factors, 869-870  
 selection criteria, for candidates, 868-869  
 selection criteria, for donor animals, 872  
 surgery, timing of, 870-872  
 techniques, complications, and immunosuppression, 874-882  
 complications, intraoperative and perioperative, 877-878  
 complications, long-term, 878-879  
 future prospects, 881

graft rejection, acute, treatment of, 880  
 immunosuppression, 879-880  
 surgical techniques, 874-877  
 survival, projected, 880-881

## S

S-Adenosylmethionine, 600-603

Soft-tissue mineralization (see Hypercalcemia)

Synovitis (see Deracoxib, effect of)

## T

Thoracic trauma, blunt, in dogs (see Myocardial injury)

Thromboembolism, aortic, associated with feline hypertrophic cardiomyopathy, 478-482

management, 480-481  
 prevention, 479-480  
 prognosis, 481

Thyroid function, canine, influence of various medications on, 511-523

amiodarone, 518-519  
 anticonvulsants, 517-518  
 cytokines, 519-520  
 furosemide, 518  
 glucocorticoids, 516-517  
 heparin, 520  
 NSAIDs, 515-516  
 physiology, thyroid, 512-513  
 propranolol, 518  
 radiocontrast agents, 520  
 ranitidine, 518  
 sulfonamides, 513-515  
 thyroxine supplementation, 520  
 tricyclic antidepressants, 518

## U

Uroabdomen, in dogs and cats, 604-612

causes, 604-605  
 diagnosis, 605-608  
 pathophysiologic consequences, 605  
 treatment, 608-611

## V

Vaccine technology (see Recombinant vaccine technology)

Vector-borne diseases

diagnostic and preventive strategies for, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 61S-65S  
 emerging importance of, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 28S-31S  
 Web sites on, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 66S

Virus transmission, interspecies, 390-397

consequences of, 392  
 crossover into humans, likelihood of, 394  
 detection of infection, focusing on, 393  
 examples of, 391  
 incidence of, 392

mechanisms of persistence, in animal populations, 392-393  
vaccination strategies, effects on, 393-394

**W****Wound management**

using honey, 53-60  
antibacterial activity, variations in different honeys, 54-55  
dressing technique, 58-59  
healing properties, 53-54  
history, 53  
versus conventional treatment, 56-58

using sugar, 41-50  
clinical studies, using sugar therapy, 43  
dressing technique, using sugar, 43-49  
healing properties, of sugar, 42  
sugar paste, use of, 42-43

**Z**

Zinc toxicosis, in small animals, 712-720  
clinical signs, 715  
diagnosis, 716  
laboratory findings, 715-716  
monitoring, 719

pharmacokinetics, 712-714  
toxic effects, 714-715  
treatment, 716-719

Zoonosis, *Bayer Zoonosis Symposium*, May supplement (5A)

*Giardia*, 105-145

helminths, knowledge and attitudes about, 45-95

ownership, pet, by immunocompromised people, 155-255

Zoonotic ascarids, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), S47-S52

## EQUINE AUTHOR INDEX

**A**

Andrews, F. M., 166  
Aubin, M. L., 411

**B**

Bentz, B. G., 734, 817  
Blak, M. A., 734, 817  
Bolt, D. M., 724  
Boyles, J., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Brashier, M. K., 242  
Bratton, C., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Braxmaier, U., 488  
Burba, D. J., 724

**C**

Cashman, C. P., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Cornell, K. K., 891  
Costa, I. R. R., 562

**D**

Dabarciner, R. M., 652  
de la Calle, J., 640  
Dirikolu, L., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Divers, T. J., 892

**E**

Eilts, B., 562  
Erkert, R. S., 734, 817

**F**

Foy, J. M., 242

**G**

Grevenmeyer, B., 488

Grooters, A. M., 812

**H**

Harkins, J. D., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Hubert, J. D., 812  
Hughes, C., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Hunter, J. M., 166  
Huxtable, C., 892

**J**

Jansson, N., 888  
Jones, S. L., 342  
Judd, R. C., 62

**K**

Karpiesiuk, W., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Koch, C., 562

**L**

Lakritz, J., 256  
Lech, P. J., 484  
Lehner, A. E., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Little, D., 342  
Lucroy, M. D., 570, 970

**M**

Mama, K., 411  
May, K. A., 150, 570, 970  
Mayer, B., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
McClure Blackmer, J., 562  
Merritt, A. M., 344  
Moll, H. D., 150, 570, 970  
Mollett, B. A., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S

December supplement (12A), 33S-43S  
Moogan, P. K., 964

**P**

Paccamonti, D., 562  
Parvianen, A. K., 73  
Peck, S., 169  
Peroni, J., 490  
Porter, B., 892

**R**

Ramey, D. W., 418  
Rashmir-Raven, A. M., 242  
Redding, W. R., 342  
Rohrbach, B. W., 166  
Rumbaugh, M. L., 640

**S**

Schroedter, D., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Semrad, S., 169  
Snook, C. S., 338  
Stanar, L. S., 342

**T**

Tetens, J., 640  
Tiidus, P. M., 418  
Tillotson, K., 964  
Tobin, T., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S  
Traub-Dargatz, J. L., 964  
Troppmann, A., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S

## V

Van Biervliet, J., 892

## W

White, S. L., 75  
 Whitlock, R. H., 166  
 Williams, J., 724  
 Wilson, W. D., 256  
 Woods, W. E., *Veterinary Therapeutics Highlights*,  
 December supplement (12A), 33S-43S

## VOLUME 24 PAGINATION: Equine

Issue	Pages	Issue	Pages
January	62-76	July	562-576, 580
February	150-172, 176	August	638-655
March	241-261	September	723-742
April	336-347	October	812-822
May	410-423	November	888-822
June	484-494, 499	December	964-976

EQUINE SUBJECT INDEX<sup>a</sup>

## A

Abdominal trauma, laparoscopic assessment of,  
 490-494  
 Albuterol, detection times for, *Veterinary  
 Therapeutics Highlights*, December supplement  
 (12A), 33S-43S  
 Anal atresia, in a foal, 888-890  
 Anesthetic techniques, field, 411-417  
   anesthetic agents, 413-414  
   anesthetic maintenance, 414-415  
   preinduction sedation, 411-413  
   recovery, 415  
   support and monitoring, 415  
 Anorectoplasty and temporary tube cystostomy in  
 small animals, 891  
 Atrial fibrillation  
   evaluation of, 734-740  
     clinical evaluation, 735-738  
     epidemiology, 734-735  
     pathogenesis, 735  
   treatment and prognosis, 817-822

## B

Botulism, 166-172

## C

Castration complications, recognition and  
 management of, 150-162  
   complications, other, 161  
   intraoperative consideration, 152-154  
   postoperative complications, long-term,  
   158-161  
   preoperative considerations, 150-152  
   short-term postoperative complications,  
   154-158

## D

Dental prophylaxis, using a pneumatic system,  
 62-70

<sup>a</sup>Page numbers ending in "S" indicate subjects  
 that appeared in a supplement to *Compendium*.

evaluation and maintenance form, 64  
 examination, 63-66  
 older horses, 69-70  
 pneumatic instruments, 66-67  
 routine floating procedure, 67-69  
 weanlings and yearlings, 69

Direct ventral hernia, 488-494

## E

Erythromycin, 256-261  
   adverse reactions, in foals, 258  
   erythromycin formulations, oral, 256-257  
   macrolide antibiotics, nonantimicrobial  
   activities of 258  
   macrolide antibiotics, other, 257  
   oral formulations, 257-258

## G

Genital tumors, external  
   recognizing, 970-976  
     examination/surveillance, 970-971  
     melanoma, 973-974  
     other tumors, 975  
     sarcoma, 974-975  
     squamous cell carcinoma, 971-972  
     squamous papilloma, 972-973  
   surgical treatment of, 570-576  
     circumferential postectomy, 572  
     cryotherapy, 572  
     drugs, anticancer, perioperative  
     administration of, 574-575  
     en bloc resection, 573-574  
     laser ablation, 571  
     local excision, 571  
     phallectomy, 572-573  
 Glomerulonephritis, 892-902  
   case report, 897-898  
   diagnosis and classification, 896-900

pathogenesis, 892-896  
 treatment and prognosis, 900

## I

Idiopathic eosinophilic enteritis, 342-347

## M

Massage therapy, assessing effectiveness of,  
 418-423

## N

Navicular bursa injections, indications for the use  
 of, 652-654  
 Neonatal isoerythrolysis, strategies for preventing,  
 562-569  
   pathogenesis, 562-564  
   strategies, 564-568

## P

Partial parenteral nutrition, in equine neonatal  
 clostridial enterocolitis, 964-969  
 Ponazuril, 484-485  
 Pythiosis, 812-815  
   diagnosis, 812-813  
   immunotherapy, 813-814  
   medical therapy, 813  
   surgical therapy, 813

## R

Round bale grass hay (see Botulism)

## S

Septic phylitis, in a foal, 73-76  
 Shoulder lameness, 640-650  
   osseous lesions, 641-646  
   soft tissue lesions, 646-648  
 Skin tumors, common, 242-254  
   melanoma, 251-252  
   sarcoma, 242-248  
   squamous cell carcinoma, 248-251



**T**

Tarsal bones, large, traumatic injuries of, 724-733  
 anatomy, 724-726  
 clinical signs and diagnosis, 726-728  
 etiology, 726

fractures, of the calcaneus, 729-730

fractures, of the malleoli, 728-729

fractures, of the talus, 730-732

Torpex™, *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435

**W**

West Nile virus, 338-340

diagnosis, 339

prevention and control, 340

spread, 338-339

treatment, 339-340

## FOOD ANIMAL AUTHOR INDEX

**A**

Al-Rawashdeh, O. E., S50

**C**

Callan, R. J., S25

Capucille, D. J., S66

**D**

DePeters, E., S82

Divers, T. J., S18

Dritz, S. S., S2

**E**

Elam, T. E., S10

**F**

Fleck Veenhuizen, M., S10

**G**

Goodband, R. D., S2

Gumaa, A. Y., S50

**H**

House, J. K., S82

**K**

Kenyon, S. J., S50

Kinsel, M. L., S34

**N**

Nelssen, J. L., S2

Niles, D., S44

Nour, A. Y. M., S50

**P**

Panarella, M., S40

Peck, S. F., S18

Poore, M. H., S66

**R**

Rager, K., S82

Rebhun, B. C., S18

Risco, C. A., S44, S56, S74, S92

Rogers, G. M., S66

**S**

Smith, B. L., S56, S74, S92

Soenksen, N., S10

**T**

Thatcher, M. J., S44

Tolkach, M. D., S2

**V**

Van Metre, D. C., S25

## VOLUME 24 PAGINATION: Food Animal

Issue	Pages
February	S1-S16
March	S17-S32
April	S33-S48
August	S49-S64
September	S66-S80
October	S81-S100

## FOOD ANIMAL SUBJECT INDEX

**A**

Abortion problems, in dairy herds, an epidemiologic approach to investigating, S34-S39

data, collecting and processing the, S36-S38

problem, confirming the, S35-S36

risk group-based sampling, S38

Artificial insemination and natural service pregnancy rates in dairy herds, seasonal evaluation of, S44-S48

herds, S45-S46

pregnancy rates, S46-S48

statistical analysis, S46

**C**

Calf nutrition, S82-S91

calf starters and milk replacers, S88

cost comparisons, S85-S87

cost versus growth requirements, S87-S88

cost versus nutritional ingredients, S82-S85

growth rate and energy partitioning, S88-S89

water requirements, S88

Castration, in cattle, S66-S73

animal welfare issues, S69-S71

techniques, S66-S69

**F**

Fenbendazole, S40-S43

cautions, S42-S43

dosage and administration, S43

drug interactions, S43

indications, S40-S42

pharmacology, S40

preparations, S43

toxicity, acute, S43

**H**

Herd expansion, dairy, health and production problems associated with, S50-S55

expansion, and overcrowding, S51-S52

expansion strategy, S52-S54

Hypokalemia, in dairy cattle, S18-S24

acid-base issues, and potassium balance, S19

clinical signs, S20

gastrointestinal disease, S20-S21

insulin, glucose, and potassium balance, S19

muscle weakness, S21-S22

nutritional issues, S19-S20

pathophysiology, S20

potassium homeostasis, physiology of, S18-S19

recumbency, S21-S22

renal disease, S21

treatment, S22-S23

## P

Porcine proliferative enteropathy, diagnosis and impact, S10-S14

- clinical disease, S11
- diagnosis, S11-S13
- economic impact, S14
- epidemiology and prevalence, S13
- herd performance, impact on, S14

Postpartum metritis in dairy cattle

- clinical manifestation of, S56-S64
  - classification, S59-S60
  - diagnosis, S60-S62
  - incidence of, S60
  - mechanisms, anatomic and protective, S57-S58
  - uterine involution, postpartum, S58-S59
- predisposing factors and potential causes of, S74-S80
  - risk factors, S75-S77
  - uterine pathogens, S77-S79
- therapeutic and management options for, S92-S100
  - antimicrobial therapy, S95-S97
  - hormonal therapy, S93-S95

Preputial injuries in bulls, evaluation and medical treatment of, S25-S32

- evaluation, S26-S28
- pathogenesis, S25-S26
- prognosis, S28-S29
- reevaluation, S31
- treatment, S29-S31
- treatment, decision for, S29

## W

Weight variation, managing, to improve feeding plans for nursery pigs, S2

- feed budget, developing the, S6-S7
- feeding strategies, S7-S8
- weaning weight, variation in, S3-S6

## SEPTEMBER 2002 QUIZ ANSWERS

## ARTICLE #1

Collection and Assessment of Canine Bone Marrow—D. J. Weiss, S. A. Smith

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. a | 2. c | 3. e | 4. b | 5. a  |
| 6. d | 7. a | 8. e | 9. d | 10. d |

## ARTICLE #2

Genetic Control of Canine Hip Dysplasia—A. S. Kapatin, P. D. Mayhew, G. K. Smith

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. a | 2. d | 3. c | 4. b | 5. a  |
| 6. d | 7. b | 8. b | 9. c | 10. a |

## ARTICLE #3

*Helicobacter*: Comparing Effects in Humans and Animals—B. Flatland

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. c | 2. d | 3. d | 4. a | 5. b  |
| 6. c | 7. c | 8. d | 9. b | 10. d |

## ARTICLE #4

Cranial Vena Cava Syndrome—A. Nicastro, E. Côté

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. c | 2. b | 3. a | 4. c | 5. b  |
| 6. a | 7. a | 8. c | 9. d | 10. b |

## ARTICLE #5

Zinc Toxicosis in Small Animals—R. Cabill-Monaco, M. A. DePasquale

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. a | 2. d | 3. b | 4. c | 5. d  |
| 6. b | 7. d | 8. b | 9. a | 10. c |

## ARTICLE #6

Traumatic Injuries of the Large Tarsal Bones in Horses—D. M. Bolt, J. Williams, D. J. Burba

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. c | 2. a | 3. d | 4. b | 5. c  |
| 6. d | 7. a | 8. a | 9. d | 10. c |

## ARTICLE #7

Atrial Fibrillation in Horses: Pathogenesis and Clinical Evaluation—B. G. Bentz, R. S. Erkert, M. A. Blaik

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. a | 2. e | 3. c | 4. d | 5. e  |
| 6. e | 7. b | 8. c | 9. d | 10. e |

## ARTICLE #8

Castration in Cattle: A Review of Techniques and Animal Welfare Aspects—D. J. Capucille, M. H. Poore, G. M. Rogers

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. e | 2. b | 3. c | 4. d | 5. a  |
| 6. b | 7. e | 8. e | 9. e | 10. d |

## ARTICLE #9

Predisposing Factors and Potential Causes of Postpartum Metritis in Dairy Cattle—B. J. Smith, C. A. Rice

- |      |      |      |      |       |
|------|------|------|------|-------|
| 1. c | 2. a | 3. b | 4. d | 5. d  |
| 6. d | 7. a | 8. b | 9. d | 10. b |

## Desmopressin (continued from page 963)

is available in 1-ml ampules and 10-ml multiple-dose vials at a concentration of 4 µg/ml.<sup>1</sup> DDAVP tablets (0.1 and 0.2 mg) are also available but are not recommended because they are destroyed in the gastrointestinal tract.<sup>1</sup>

## STORAGE AND HANDLING

Refrigeration is recommended for both nasal and parenteral DDAVP solutions.<sup>1</sup> However, an unopened bottle of nasal solution is stable for 3 weeks at room temperature.<sup>1</sup> DDAVP should not be frozen. Tablets should be stored at room temperature.

## REFERENCES

1. Plumb DC: *Veterinary Drug Handbook*, ed 3. Ames, Iowa State University Press, 1999, pp 203-205.

2. Nichols R, Hohenhaus AE: Use of the vasopressin analogue desmopressin for polyuria and bleeding disorders. *JAVMA* 205(2):168-173, 1994.
3. Kraus KH: The use of desmopressin in diagnosis and treatment of diabetes insipidus in cats. *Compend Contin Educ Pract Vet* 9(7):752-755, 1987.
4. Mansell PD, Parry BW: Changes in factor VIII: Coagulant activity and von Willebrand factor antigen concentration after subcutaneous injection of desmopressin in dogs with mild hemophilia A. *J Vet Intern Med* 5(3):191-194, 1991.
5. Johnstone IB, Crane S: The effects of desmopressin on hemostatic parameters in the normal dog. *Can J Vet Res* 50:265-271, 1986.
6. Johnstone IB: Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with type I von Willebrand's disease. *Can Vet J* 40: 645-648, 1999.

